Primary Angiosarcoma Arising in an Angiomyolipoma of the Kidney: Case
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Hemangiosarcoma Philip J
Ettinger & Feldman – Textbook of Veterinary Internal Medicine Client Information Sheet Hemangiosarcoma Philip J. Bergman What is hemangiosarcoma? Hemangiosarcoma (HSA; angiosarcoma or malignant hemangioendothelioma) is an extremely aggressive tumor of blood vessel origin. Because blood vessels are present throughout the body, virtually any site in the body can have HSA. HSA occurs most frequently in dogs (approximately 2% of all tumors) and the most common site is the spleen. However, additional common sites include the heart, liver, muscle, lung skin, bones, kidney, brain, abdomen, and oral cavity. In three large canine splenic disease studies encompassing approximately 2000 dogs, a “rule of two thirds” was found suggesting that approximately two thirds of dogs with a splenic mass have a cancer (therefore one third are not malignant) and two thirds of the malignant tumors of the spleen are HSA. HSA is a disease generally of older dogs and cats with an average onset of 9 to 10 years; however, there are reports of extremely young dogs and cats with this disease (5 to 6 months to a few years of age). German shepherd dogs are most commonly diagnosed with HSA; however, other large breed dogs such as golden retrievers and Labrador retrievers may also be overrepresented. In cats, the most common breed is the domestic shorthair. The cause of HSA in dogs and cats is presently unknown. Exposures to toxins such as chemicals, insecticides, and radiation have been reported in humans to be associated with HSA. Ultraviolet light exposure from the sun may be a potential cause of HSA in dogs, as HSAs of the skin are commonly seen in dogs with light hair and poor pigmentation (e.g., Salukis, Whippets, and white Bulldogs). -
Tumors and Tumor-Like Lesions of Blood Vessels 16 F.Ramon
16_DeSchepper_Tumors_and 15.09.2005 13:27 Uhr Seite 263 Chapter Tumors and Tumor-like Lesions of Blood Vessels 16 F.Ramon Contents 42]. There are two major classification schemes for vas- cular tumors. That of Enzinger et al. [12] relies on 16.1 Introduction . 263 pathological criteria and includes clinical and radiolog- 16.2 Definition and Classification . 264 ical features when appropriate. On the other hand, the 16.2.1 Benign Vascular Tumors . 264 classification of Mulliken and Glowacki [42] is based on 16.2.1.1 Classification of Mulliken . 264 endothelial growth characteristics and distinguishes 16.2.1.2 Classification of Enzinger . 264 16.2.1.3 WHO Classification . 265 hemangiomas from vascular malformations. The latter 16.2.2 Vascular Tumors of Borderline classification shows good correlation with the clinical or Intermediate Malignancy . 265 picture and imaging findings. 16.2.3 Malignant Vascular Tumors . 265 Hemangiomas are characterized by a phase of prolif- 16.2.4 Glomus Tumor . 266 eration and a stationary period, followed by involution. 16.2.5 Hemangiopericytoma . 266 Vascular malformations are no real tumors and can be 16.3 Incidence and Clinical Behavior . 266 divided into low- or high-flow lesions [65]. 16.3.1 Benign Vascular Tumors . 266 Cutaneous and subcutaneous lesions are usually 16.3.2 Angiomatous Syndromes . 267 easily diagnosed and present no significant diagnostic 16.3.3 Hemangioendothelioma . 267 problems. On the other hand, hemangiomas or vascular 16.3.4 Angiosarcomas . 268 16.3.5 Glomus Tumor . 268 malformations that arise in deep soft tissue must be dif- 16.3.6 Hemangiopericytoma . -
Cutaneous Angiosarcoma: Report of Three Different and Typical Cases Admitted in a Unique Dermatology Clinic*
CASE REPORT 235 s Cutaneous angiosarcoma: report of three different and typical cases admitted in a unique dermatology clinic* Aline Neves Freitas Cabral1 Rafael Henrique Rocha1 Ana Cristina Vervloet do Amaral1 Karina Bittencourt Medeiros2 Paulo Sérgio Emerich Nogueira1 Lucia Martins Diniz3 DOI: http://dx.doi.org/10.1590/abd1806-4841.20175326 Abstract: Angiosarcoma is a rare and aggressive tumor with high rates of metastasis and relapse. It shows a particular predi- lection for the skin and superficial soft tissues. We report three distinct and typical cases of angiosarcoma that were diagnosed in a single dermatology clinic over the course of less than a year: i) Angiosarcoma in lower limb affected by chronic lymph- edema, featuring Stewart-Treves syndrome; ii) a case of the most common type of angiosarcoma loated in the scalp and face of elderly man and; iii) a skin Angiosarcoma in previously irradiated breast. All lesions presented characteristic histopathological findings: irregular vascular proliferation that dissects the collagen bundles with atypical endothelial nuclei projection toward the lumen. Keywords: Hemangiosarcoma; Lymphangiosarcoma; Lymphedema; Non-Filarial Lymphedema; Sarcoma INTRODUCTION Angiosarcoma (AS) is a rare and aggressive neoplasm, that fibers, formed by endothelium with atypical nuclei, prominent to- originates from endothelial cells of lymphatic and blood vessels. It ac- ward the lumen; The tumoral lesion exhibited cohesive epithelioid counts for 5% of malignant skin tumors and less than 1% of all sarco- masses of atypical, large, rounded cells with acidophilic cytoplasm mas. It is notable for having a predilection for the skin and superficial and frequent mitotic figures. (Figure 2). Immunohistochemical anal- soft tissues. -
The Health-Related Quality of Life of Sarcoma Patients and Survivors In
Cancers 2020, 12 S1 of S7 Supplementary Materials The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany—Cross-Sectional Results of A Nationwide Observational Study (PROSa) Martin Eichler, Leopold Hentschel, Stephan Richter, Peter Hohenberger, Bernd Kasper, Dimosthenis Andreou, Daniel Pink, Jens Jakob, Susanne Singer, Robert Grützmann, Stephen Fung, Eva Wardelmann, Karin Arndt, Vitali Heidt, Christine Hofbauer, Marius Fried, Verena I. Gaidzik, Karl Verpoort, Marit Ahrens, Jürgen Weitz, Klaus-Dieter Schaser, Martin Bornhäuser, Jochen Schmitt, Markus K. Schuler and the PROSa study group Includes Entities We included sarcomas according to the following WHO classification. - Fletcher CDM, World Health Organization, International Agency for Research on Cancer, editors. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013. 468 p. (World Health Organization classification of tumours). - Kurman RJ, International Agency for Research on Cancer, World Health Organization, editors. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: International Agency for Research on Cancer; 2014. 307 p. (World Health Organization classification of tumours). - Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Jul;70(1):106–19. - World Health Organization, Swerdlow SH, International Agency for Research on Cancer, editors. WHO classification of tumours of haematopoietic and lymphoid tissues: [... reflects the views of a working group that convened for an Editorial and Consensus Conference at the International Agency for Research on Cancer (IARC), Lyon, October 25 - 27, 2007]. 4. ed. -
The Nutrition and Food Web Archive Medical Terminology Book
The Nutrition and Food Web Archive Medical Terminology Book www.nafwa. -
Toxicological Profile for Glyphosate Were
A f Toxicological Profile for Glyphosate August 2020 GLYPHOSATE II DISCLAIMER Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services. GLYPHOSATE III FOREWORD This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary. The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced. The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's -
Glomus Tumor in the Floor of the Mouth: a Case Report and Review of the Literature Haixiao Zou1,2, Li Song1, Mengqi Jia2,3, Li Wang4 and Yanfang Sun2,3*
Zou et al. World Journal of Surgical Oncology (2018) 16:201 https://doi.org/10.1186/s12957-018-1503-6 CASEREPORT Open Access Glomus tumor in the floor of the mouth: a case report and review of the literature Haixiao Zou1,2, Li Song1, Mengqi Jia2,3, Li Wang4 and Yanfang Sun2,3* Abstract Background: Glomus tumors are rare benign neoplasms that usually occur in the upper and lower extremities. Oral cavity involvement is exceptionally rare, with only a few cases reported to date. Case presentation: A 24-year-old woman with complaints of swelling in the left floor of her mouth for 6 months was referred to our institution. Her swallowing function was slightly affected; however, she did not have pain or tongue paralysis. Enhanced computed tomography revealed a 2.8 × 1.8 × 2.1 cm-sized well-defined, solid, heterogeneous nodule above the mylohyoid muscle. The mandible appeared to be uninvolved. The patient underwent surgery via an intraoral approach; histopathological examination revealed a glomus tumor. The patient has had no evidence of recurrence over 4 years of follow-up. Conclusions: Glomus tumors should be considered when patients present with painless nodules in the floor of the mouth. Keywords: Glomus tumor, Floor of mouth, Oral surgery Background Case presentation Theglomusbodyisaspecialarteriovenousanasto- A 24-year-old woman with a 6-month history of swelling mosisandfunctionsinthermalregulation.Glomustu- in the left floor of her mouth was referred to our institu- mors are rare, benign, mesenchymal tumors that tion. Although she experienced slight difficulty in swal- originate from modified smooth muscle cells of the lowing, she did not experience pain or tongue paralysis. -
Angiosarcomas and Other Sarcomas of Endothelial Origin
Angiosarcomas and Other Sarcomas of Endothelial Origin a,b a Angela Cioffi, MD , Sonia Reichert, MD , c a,b,d, Cristina R. Antonescu, MD , Robert G. Maki, MD, PhD, FACP * KEYWORDS Angiosarcoma Epithelioid hemangioendothelioma Vascular sarcoma Kaposi sarcoma VEGF KDR FLT4 Translocation Organ transplant KEY POINTS Vascular sarcomas are rare and collectively affect fewer than 600 people a year in the United States (incidence approximately 2/million). Because angiosarcomas, hemangioendotheliomas, and other vascular tumors have unique embryonal derivation, it is not surprising that they have a unique sensitivity pattern to chemotherapy agents. Surgery, when possible, remains the primary treatment for angiosarcomas. Adjuvant radiation for primary disease seems prudent for at least some angiosarcoma, given the high local-regional recurrence rate of these tumors. Angiosarcomas also have a high rate of metastasis, but it is not clear that adjuvant chemotherapy improves survival. Epithelioid hemangioendothelioma is a unique form of sarcoma often presenting as multi- focal disease. Most patients can do well with observation alone, although a fraction of pa- tients have more aggressive disease and have difficulties in both local control and metastatic disease. Continued Disclosures: R.G. Maki receives clinical research support from Morphotek/Eisai, Ziopharm, and Imclone/Lilly. He has also consulted for Eisai, Morphotek/Eisai, Imclone/Lilly, Taiho, Glaxo- SmithKline, Merck, Champions Biotechnology, and Pfizer. He has received speaker’s fees from Novartis. He is an unpaid consultant for the Sarcoma Foundation of America, SARC: Sarcoma Alliance for Research through Collaboration, n-of-one, and 23 & me. C.R. Antonescu, A. Cioffi, and S. Reichert report no conflicts. -
About Soft Tissue Sarcoma Overview and Types
cancer.org | 1.800.227.2345 About Soft Tissue Sarcoma Overview and Types If you've been diagnosed with soft tissue sarcoma or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is a Soft Tissue Sarcoma? Research and Statistics See the latest estimates for new cases of soft tissue sarcoma and deaths in the US and what research is currently being done. ● Key Statistics for Soft Tissue Sarcomas ● What's New in Soft Tissue Sarcoma Research? What Is a Soft Tissue Sarcoma? Cancer starts when cells start to grow out of control. Cells in nearly any part of the body can become cancer and can spread to other areas. To learn more about how cancers start and spread, see What Is Cancer?1 There are many types of soft tissue tumors, and not all of them are cancerous. Many benign tumors are found in soft tissues. The word benign means they're not cancer. These tumors can't spread to other parts of the body. Some soft tissue tumors behave 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 in ways between a cancer and a non-cancer. These are called intermediate soft tissue tumors. When the word sarcoma is part of the name of a disease, it means the tumor is malignant (cancer).A sarcoma is a type of cancer that starts in tissues like bone or muscle. Bone and soft tissue sarcomas are the main types of sarcoma. Soft tissue sarcomas can develop in soft tissues like fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues. -
A Case of Lymphangioleiomyomatosis Originated in the Pelvic Cavity
J Gynecol Oncol Vol. 19, No. 3:195-198, September 2008 DOI:10.3802/jgo.2008.19.3.195 Case Report A case of lymphangioleiomyomatosis originated in the pelvic cavity Jung-Mi Han, Kyung-Hee Lee, Sung-Joo Kim, Chae-Chun Rhim, Young-Han Park, Jung-Bae Kang, Sun-Young Jeon1 Departments of Obstetrics and Gynecology, 1Pathology, Hallym University Medical College, Anyang, Korea Lymphangioleiomyomatosis is a rare disease that is characterized by proliferation of abnormal smooth muscle-like cells, especially that which occurs in the pulmonary parenchyme. It primarily affects women of child-bearing age. The majority of primary lymphangioleiomyomatosis occurs in the lung, but there are a few reports of extrapulmonary cases. We experienced a rare case of lymphangioleiomyomatosis which originated in the pelvic cavity (in the posterior portion of the uterus), and report with brief review of literatures. Key Words: Lymphangioleiomyomatosis, Pelvis, Uterus INTRODUCTION hypervascular tumor between the uterus and the right ovary, and two small myomas about 2 cm in size (Fig. 1). Under the Lymphangioleiomyomatosis is a very rare disease which impression of ovarian malignancy she had admitted for shows typical features of abnormal smooth muscle cell further evaluation including MRI. Her initial serum CA-125 proliferation and which develops in females during the level was 26.7 U/ml and CA 19-9 level was below 2 U/ml, and reproductive period.1,2 The majority cases of this disease other hematologic findings were all within the normal range. primarily occur in the lungs, but extrapulmonary regions such Magnetic resonance imaging study of the abdomen-pelvis as the pelvis and retroperitoneal spaces are occasionally demonstrated an approximately 4.0×5.0×4.0 cm sized tumor primary sites. -
Lymphangioleiomyomatosis and Tuberous Sclerosis: Where Is the Border?
Eur Respir J, 1996, 9, 399–401 Copyright ERS Journals Ltd 1996 DOI: 10.1183/09031936.96.09030399 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 EDITORIAL Lymphangioleiomyomatosis and tuberous sclerosis: Where is the border? F. Bonetti*, P. Chiodera** Pulmonary lymphangioleiomyomatosis (PLAM) is a The key to addressing this unresolved question seems rare disease, characterized by an abnormal proliferation to be the definition of the diagnostic criteria of TS. The of smooth muscle throughout the lung; it occurs exclu- classical Vogt triad (seizures, mental retardation and facial sively in women, generally of reproductive age [1]. The angiofibroma) was the first important attempt to clini- muscle cells proliferating in PLAM show little or no cally define the syndrome. This diagnostic triad was atypia at histological level. Therefore, PLAM has been universally accepted and was, for a long time, consi- considered to be a hamartomatous lesion rather than a dered the hallmark of the disease. Whilst useful for clini- true neoplastic process. However, in spite of the bland cians, this approach led to a delay in the recognition of cytological features, the disease causes a progressive other diagnostic signs of TS, particularly the presence structural remodelling of the lung, leading to serious and classification of visceral lesions, such as angio- impairment of pulmonary function. Whilst survival curves myolipoma, so characteristic in this hereditary disease of now seem better than previously believed and hormonal autosomal dominant transmission. With the accumula- treatment has been introduced with encouraging results tion of knowledge on TS and the introduction of new [2], some patients progress to a condition necessitating diagnostic techniques, the Vogt triad has lost much of lung transplantation. -
Differential Diagnostic Considerations
Radiology Case Reports Volume 10, Issue 2, 2015 Chylothorax in a patient with metastatic Kaposi sarcoma: Differential diagnostic considerations Ryan Alexander, DO; Magda Rizer, DO; William Burke, MD; and Lawrence Ciment, MD Kaposi sarcoma (KS) is a low-grade mesenchymal tumor involving blood and lymphatic vessels. There are four types, based on clinical presentation: classic, endemic (Africana), iatrogenic (typically, involving renal allograft recipients), and AIDS-associated (epidemic). Kaposi’s sarcoma-associated herpes virus in- fection has been linked along with other factors to the development of KS. The Kaposi’s sarcoma- associated herpes virus interacts and encodes for numerous molecular proteins that play a role in the pathogenesis of KS, including latency-associated nuclear antigen, viral G protein-coupled receptor, viral FLICE inhibitory protein, and viral IL-6. KS primarily affects the skin and causes disseminated disease in a variety of organs. Involvement of visceral organs other than the lining of the alimentary tract is ex- tremely rare. While the chylous pleural effusions of KS may resemble other pulmonary diseases (includ- ing lymphangioma, lymphangectasis, and lymphangioleiomyomatosis) with chylous effusions at thoracic CT, differentiating features may allow for more prompt diagnosis and treatment. The presumptive diag- nosis of AIDS-related pulmonary KS is often clinical. A tissue diagnosis is not required to establish the diagnosis of pulmonary KS. There are a variety of causes of chylothorax. The primary finding is a near- water-attenuating pleural effusion. The secondary findings of chylothorax can help differentiate the etiology. Introduction be diagnosed on CT or MRI. The CT finding of chylous Chylothorax is a relatively uncommon cause of pleural effusions is typically a large unilateral effusion of water effusion (1).